08:46 AM EDT, 08/07/2025 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) reported Q2 core adjusted net income Thursday of $1.60 per diluted share, up from $1.40 a year ago.

Analysts polled by FactSet expected $1.42.

Revenue for the quarter ended June 30 was $47.6 million, up from $41.5 million a year earlier.

Analysts surveyed by FactSet expected $43.9 million.

The company said it now expects 2025 adjusted earnings of $6.70 to $7.00 per diluted share, higher than its previous guidance of $6.00 to $6.25, on revenue of $200 million to $225 million, higher than its previous range of $180 million to $200 million.

Analyst polled by FactSet expect 2025 earnings of $6.12 on revenue of $194 million.